Press release -
Chr. Hansen acquires Urex Biotech Inc.
With the acquisition Chr. Hansen expands its activities within proven probiotics for dietary supplements.
“I am very pleased with this agreement. As a division our strategy is to continue the recent year’s positive development through organic growth or through relevant acquisitions - and Urex is a perfect strategic fit for us,” says Henrik Dalboege, Executive Vice President, Health & Nutrition Division, Chr. Hansen.
The Health & Nutrition Division experienced more than 20% organic growth in 2007/08 and has positive prospects for the future too. The focus is on developing new products for the dietary supplement industry and the pharmaceutical industry, first and foremost with focus on probiotics.
Best documented
Urex is a convenient oral probiotic concept clinically documented to restore and maintain a healthy vaginal flora which may reduce the risk of infections. Over the last few years nine clinical studies conducted in several countries have been published using the oral formulation and numerous others are currently underway.
“For probiotics documentation is key and Urex –cap-5 is among the best documented probiotic concepts in the world. Furthermore, the concept fits perfectly to our existing product portfolio within the category women’s health and to our other probiotic solutions for gastrointestinal health and immune health,” Mr. Dalboege continues.
Urex is today sold in many markets worldwide e.g. the US, France, Poland and India.
Close cooperation
In 2004 Chr. Hansen and Urex Biotech Inch. entered into a strategic alliance on developing and promoting therapeutic solutions to women’s health issues based on proven probiotic strains.
“We have enjoyed a very rewarding cooperation with Urex and we plan to continue our cooperation with the co-founder and internationally recognized probiotic researcher Dr. Gregor Reid in the future too", Mr. Dalboege concludes.
“Dr. Bruce and I accomplished what we set out to do with Urex, namely develop technology that could provide benefits for the urogenital health of women. But our hearts are in medical science and the time has come to return to those roots, leaving the business aspects of taking the lactobacilli to women around the world, in the safe hands of Chr. Hansen”, Dr. Reid explains.
The acquisition price is not disclosed.
###LINK OPEN###2160>Read more about womens health and probiotics###LINK CLOSE###
Topics
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.
